Minaris and Asimov Partner to Advance AAV Manufacturing with OXGENE Technology

Asimov to integrate Minaris’ OXGENE technology into its AAV Edge producer cell lines to unlock higher manufacturing titers and improved product quality.

‍

Philadelphia, PA & Boston, MA – September 24, 2026 – Minaris, a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization, and Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a partnership that enables higher performing producer cell lines for production of adeno-associated virus (AAV) gene therapies.

‍

AAV manufacturing remains a significant challenge for developers using this delivery modality for gene therapies, where large quantities of vectors are required and product quality is paramount. Through OXGENE, Minaris’ center of excellence for advanced viral vector technology development, Minaris brings industry-leading optimization and engineering technology to improve AAV and lentiviral vector manufacturability, complementing its broader viral vector development and manufacturing services. Through this collaboration, Asimov will have the ability to incorporate Minaris’ proprietary OXGENE technology into its diverse toolkit for AAV Edge producer cell lines, amplifying the potential through its synthetic biology expertise to solve one of the industry’s most daunting bioproduction challenges.

‍

“Minaris is committed to enabling the cell and gene therapy industry through technology partnerships that raise the bar for manufacturing excellence,” said Eytan Abraham, Chief Commercial & Technology Officer at Minaris. “We believe in democratization of our technologies and creating a wide variety of solutions to enable the viral vector modality for patients, and are thrilled to enable Asimov in the creation of next-generation AAV producer cell lines.”

‍

Most AAV programs today still depend on transient production, which requires multiple GMP plasmids to be transfected every batch. This approach drives up costs, limits scalability, and can result in inconsistent product quality. However, stable production systems for AAV have been challenging to develop due to the immense complexity and interdependency of the viral genetics. Asimov’s AAV Edge Stable Producer System leverages genetic design expertise to solve this problem and bring forward high-titer, clonal producer cell lines. 

‍

“Stable producer cell lines are a key technology to enable AAV gene therapies at scale, and we are excited to partner with Minaris to unlock a new level of performance for our AAV Edge system,” said Raja Srinivas, Co-Founder at Asimov. “At Asimov, we have developed a genetic design toolkit that allows us to engineer high-titer cell lines, and we look forward to adding Minaris’s technology to this toolkit and building a production system purpose-built for the next generation of gene therapies.” 

‍

The agreement further strengthens Minaris’ position as an integrated viral vector development and manufacturing partner, combining proprietary technologies developed through OXGENE with broader development, manufacturing and testing capabilities that support viral vector programs from development through commercialization.

‍

About Minaris

Minaris is a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization. With more than 25 years of CGT development and manufacturing expertise and more than 40 years in biosafety testing, Minaris combines deep legacy experience with state-of-the-art GMP facilities as a fully U.S.-owned organization under new ownership and management, built for today’s evolving therapeutic landscape.

‍

Through its divisions, Minaris Advanced Therapies and Minaris Advanced Testing, the company supports innovators from IND through commercial supply and delivers GMP analytics, biosafety, viral clearance, and product characterization across CGT and biologics. With five global sites across three continents, Minaris is committed to helping partners bring more therapies to more patients worldwide.

‍

For more information, visit minaris.com or follow us on LinkedIn.

‍

About Asimov

Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform, from cells to software, to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations. 

‍

Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com.